应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
02575 轩竹生物-B
已收盘 03-20 16:08:47
43.000
-6.840
-13.72%
最高
50.850
最低
43.000
成交量
160.74万
今开
49.000
昨收
49.840
日振幅
15.75%
总市值
222.74亿
流通市值
69.10亿
总股本
5.18亿
成交额
7,228万
换手率
1.00%
流通股本
1.61亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）
资讯
新帖
简况
轩竹生物-B一度飙升60%！吡洛西利片一线适应症近日获批，入通后资金抢跑布局
老虎资讯综合 · 03-19 10:24
轩竹生物-B一度飙升60%！吡洛西利片一线适应症近日获批，入通后资金抢跑布局
轩竹生物-B(02575)涨44.57% 日前获纳入港股通 吡洛西利片一线适应症获批
金吾财讯 · 03-19 09:41
轩竹生物-B(02575)涨44.57% 日前获纳入港股通 吡洛西利片一线适应症获批
入通靴子落地加速创新价值兑现，轩竹生物-B(02575)迎关键配置窗口期
智通财经 · 03-17
入通靴子落地加速创新价值兑现，轩竹生物-B(02575)迎关键配置窗口期
轩竹生物-B(02575.HK)拟3月30日举行董事会会议审批全年业绩
中金财经 · 03-16
轩竹生物-B(02575.HK)拟3月30日举行董事会会议审批全年业绩
轩竹生物-B盘中异动 早盘快速下跌5.35%报49.500港元
市场透视 · 03-12
轩竹生物-B盘中异动 早盘快速下跌5.35%报49.500港元
港股轩竹生物-B尾盘涨超10%
每日经济新闻 · 03-09
港股轩竹生物-B尾盘涨超10%
港股公告掘金 | 蒙牛乳业预计年度股东应占利润将约为14亿元至 16亿元
智通财经 · 03-09
港股公告掘金 | 蒙牛乳业预计年度股东应占利润将约为14亿元至 16亿元
四环医药：本集团旗下非全资附属公司轩竹生物被调入沪港通与深港通下港股通标的名单。
新浪财经 · 03-09
四环医药：本集团旗下非全资附属公司轩竹生物被调入沪港通与深港通下港股通标的名单。
轩竹生物-B(02575)获纳入港股通股票名单
智通财经 · 03-08
轩竹生物-B(02575)获纳入港股通股票名单
轩竹生物-B盘中异动 早盘快速跳水5.27%
市场透视 · 03-06
轩竹生物-B盘中异动 早盘快速跳水5.27%
轩竹生物-B盘中异动 早盘大幅跳水5.08%报57.900港元
市场透视 · 03-04
轩竹生物-B盘中异动 早盘大幅跳水5.08%报57.900港元
轩竹生物-B(02575)：轩悦宁®第三个适应症上市申请获得NMPA批准，用于一线治疗HR+/HER2-晚期乳腺癌
智通财经 · 03-03
轩竹生物-B(02575)：轩悦宁®第三个适应症上市申请获得NMPA批准，用于一线治疗HR+/HER2-晚期乳腺癌
轩竹生物-B：宣愈宁比瑞西利片补充新药申请获批新适应症
美股速递 · 03-03
轩竹生物-B：宣愈宁比瑞西利片补充新药申请获批新适应症
四环医药(00460.HK)附属轩竹生物获纳入恒生综合指数成份股
中金财经 · 02-22
四环医药(00460.HK)附属轩竹生物获纳入恒生综合指数成份股
轩竹生物-B(02575)获纳入恒生综合指数成分股
智通财经网 · 02-22
轩竹生物-B(02575)获纳入恒生综合指数成分股
轩竹生物-B(02575)获纳入恒生综合指数 有望成为港股通标的
智通财经 · 02-13
轩竹生物-B(02575)获纳入恒生综合指数 有望成为港股通标的
轩竹生物-B盘中异动 下午盘股价大跌5.44%报64.300港元
市场透视 · 02-12
轩竹生物-B盘中异动 下午盘股价大跌5.44%报64.300港元
轩竹生物-B盘中异动 股价大涨5.05%
市场透视 · 02-09
轩竹生物-B盘中异动 股价大涨5.05%
轩竹生物-B盘中异动 股价大涨5.19%
市场透视 · 02-06
轩竹生物-B盘中异动 股价大涨5.19%
四环医药仿制药触底中，轩竹生物成功分拆，创新药进入收获期，惠升生物布局糖尿病全管线也迎
第一上海 · 02-06
四环医药仿制药触底中，轩竹生物成功分拆，创新药进入收获期，惠升生物布局糖尿病全管线也迎
加载更多
公司概况
公司名称：
轩竹生物-B
所属市场：
SEHK
上市日期：
--
主营业务：
轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。该公司主要从事研发、生产及商业化创新药的业务，专注于消化、肿瘤和非酒精性脂肪性肝炎（NASH）等多个治疗领域。该公司主要产品包括KBP-3571、XZP-3287及XZP-3621。该公司主要在中国国内开展业务。
发行价格：
--
{"stockData":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"轩竹生物-B","latestPrice":43,"timestamp":1773994127267,"preClose":49.84,"halted":0,"volume":1607407,"delay":0,"changeRate":-0.13723916532905303,"floatShares":160701996,"shares":518000000,"eps":-1.234826,"marketStatus":"已收盘","change":-6.84,"latestTime":"03-20 16:08:47","open":49,"high":50.85,"low":43,"amount":72276809,"amplitude":0.157504,"askPrice":43.1,"askSize":18000,"bidPrice":43,"bidSize":15000,"shortable":0,"etf":0,"ttmEps":-1.178,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774229400000},"marketStatusCode":5,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":49.84,"openAndCloseTimeList":[[1773970200000,1773979200000],[1773982800000,1773993600000]],"volumeRatio":0.99037,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02575","defaultTab":"news","newsList":[{"id":"1130891814","title":"轩竹生物-B一度飙升60%！吡洛西利片一线适应症近日获批，入通后资金抢跑布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1130891814","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130891814?lang=zh_cn&edition=full","pubTime":"2026-03-19 10:24","pubTimestamp":1773887083,"startTime":"0","endTime":"0","summary":"3月19日，轩竹生物-B一度飙升60%！轩竹股价在3月9日大幅收涨8.30%，当日股票成交额达到4838.75万港元，较年内日均成交额2244万港元，大幅上涨约116%，入通次日公司股票单日成交额继续上涨至6195.59万港元，显示出港股通资金对轩竹生物的“抢跑布局”。实际上，轩竹生物在二级市场交投活跃度快速回升并获资金抢跑布局，主要得益于市场投资者对公司明确的“创新-商业化”投资逻辑的认可。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8f3c7b18acd8da97ebbf23072ff5b0a2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"gpt_icon":1},{"id":"2620991292","title":"轩竹生物-B(02575)涨44.57% 日前获纳入港股通 吡洛西利片一线适应症获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2620991292","media":"金吾财讯","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620991292?lang=zh_cn&edition=full","pubTime":"2026-03-19 09:41","pubTimestamp":1773884484,"startTime":"0","endTime":"0","summary":"金吾财讯 | 轩竹生物-B(02575)股价大幅拉升，截至发稿，涨44.57%，报62.05港元，成交额2133万港元。消息面上，日前，沪深交易所发布公告，调整港股通标的。公告显示，港股通标的名单发生调整，并自3月9日起生效。其中，轩竹生物被调入港股通标的名单。此外，轩竹生物自研1类创新药吡洛西利片获国家药监局批准新增适应症，可联合芳香化酶抑制剂（AI），用于HR+/HER2-晚期乳腺癌患者初始内分泌治疗。这一进展标志着吡洛西利从后线治疗正式挺进一线治疗领域，为我国HR+/HER2-晚期乳腺癌患者提供了疗效卓越、安全便捷的全新治疗选择。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MjA1YmE2ZTUwNGJlNDY3ODMxMDE0ODI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976798","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","02575","BK1191","BK4588","VXUS"],"gpt_icon":0},{"id":"2620137274","title":"入通靴子落地加速创新价值兑现，轩竹生物-B(02575)迎关键配置窗口期","url":"https://stock-news.laohu8.com/highlight/detail?id=2620137274","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620137274?lang=zh_cn&edition=full","pubTime":"2026-03-17 08:26","pubTimestamp":1773707180,"startTime":"0","endTime":"0","summary":"近日，事关创新药的政策利好不断。这对于在二级市场顺利“入通”、核心创新品种一线适应症获批的轩竹生物-B而言，无疑是极大利好。“入通”靴子落地，资金抢跑布局拉长时间线来看，2025年全年，港股通日均成交额为1211亿港元，占港股整体日均成交额的比重达到26.2%。轩悦宁强势挺进乳腺癌一线治疗，引发了业界和市场广泛关注。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414657.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2619468322","title":"轩竹生物-B(02575.HK)拟3月30日举行董事会会议审批全年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468322","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619468322?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:17","pubTimestamp":1773663424,"startTime":"0","endTime":"0","summary":"格隆汇3月16日丨轩竹生物-B(02575.HK)宣布，董事会会议将于2026年3月30日(星期一)举行，藉以(其中包括)考虑及批准集团截至2025年12月31日止年度之全年业绩及其刊发，并考虑建议派发末期股息(如有)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260316/32072306.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02575","BK1191"],"gpt_icon":0},{"id":"2618905006","title":"轩竹生物-B盘中异动 早盘快速下跌5.35%报49.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618905006","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618905006?lang=zh_cn&edition=full","pubTime":"2026-03-12 10:31","pubTimestamp":1773282702,"startTime":"0","endTime":"0","summary":"2026年03月12日早盘10时31分，轩竹生物-B股票出现异动，股价快速下挫5.35%。截至发稿，该股报49.500港元/股，成交量18.7万股，换手率0.12%，振幅5.93%。资金方面，该股资金流入540.012万港元，流出361.313万港元。机构评级方面，目前暂无机构对该股做出“买入、持有、卖出”建议。轩竹生物-B股票所在的生物技术行业中，整体跌幅为1.16%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031210314295499806&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031210314295499806&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2618643080","title":"港股轩竹生物-B尾盘涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618643080","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618643080?lang=zh_cn&edition=full","pubTime":"2026-03-09 15:52","pubTimestamp":1773042721,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月9日，轩竹生物-B(02575.HK)尾盘涨超10%，截至发稿涨10.3%，报55.15港元，成交额4197.63万港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603093666060581.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603093666060581.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02575","BK4585","BK1191","BK4588","VXUS"],"gpt_icon":0},{"id":"2618369053","title":"港股公告掘金 | 蒙牛乳业预计年度股东应占利润将约为14亿元至 16亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2618369053","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618369053?lang=zh_cn&edition=full","pubTime":"2026-03-09 09:03","pubTimestamp":1773018197,"startTime":"0","endTime":"0","summary":"重大事项：恒瑞医药(01276)：阿得贝利单抗注射液获得药物临床试验批准通知书安井食品(02648)拟向河南子公司增资1.2亿元轩竹生物-B(02575)获纳入港股通股票名单派格生物医药-B(02565)：派格生物新一代GLP-1(CR059)首次人体试验取得一个月临床观察结果长风药业(02652)获纳入沪港通及深港通的港股通标的证券名单滨海投资(02886)获提供不超过4500万美元及1.73亿","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0032834883.USD","IE0009570106.USD","LU0128522157.USD","LU0211977185.USD","LU0359201612.USD","LU0287142896.SGD","IE0008368742.USD","HK0000306701.USD","BK1521","LU0348788117.USD","LU1769817179.HKD","02319","LU0672654166.SGD","BK1553","LU0072462343.USD","LU0106959298.USD","LU0029875118.USD","BK1191","IE00B031HY20.USD","LU0259732245.USD","BK1237","LU0650527681.SGD","LU1115378108.SGD","LU2045819591.USD","LU0359201885.HKD","LU0588546209.SGD","LU1769817096.USD","LU0737861699.HKD","HK0000320264.USD","LU1048588211.SGD","LU1224709979.USD","LU2125910500.SGD","LU0307460666.USD","LU0370786039.SGD","LU0651946864.USD","IE00B0169L03.USD","02652","IE00B97KM107.HKD","02575","LU0823426308.USD","LU0594300419.USD","IE00B29SXG58.USD","VT","IE00B031J352.USD","LU0315179316.USD","SG9999002828.SGD","BK1597","LU0163747925.USD","VXUS","LU0251143458.SGD"],"gpt_icon":0},{"id":"2618697300","title":"四环医药：本集团旗下非全资附属公司轩竹生物被调入沪港通与深港通下港股通标的名单。","url":"https://stock-news.laohu8.com/highlight/detail?id=2618697300","media":"新浪财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618697300?lang=zh_cn&edition=full","pubTime":"2026-03-09 07:38","pubTimestamp":1773013120,"startTime":"0","endTime":"0","summary":"来源：滚动播报四环医药：本集团旗下非全资附属公司轩竹生物被调入沪港通与深港通下港股通标的名单。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309074429a4595305&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309074429a4595305&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","02575","BK1600","BK1191","00460","BK1593"],"gpt_icon":0},{"id":"2617066429","title":"轩竹生物-B(02575)获纳入港股通股票名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2617066429","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617066429?lang=zh_cn&edition=full","pubTime":"2026-03-08 18:20","pubTimestamp":1772965216,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B(02575)发布公告，根据上海证券交易所及深圳证券交易所于2026年3月6日分别发布的《关于沪港通下港股通标的调整的通知》、《关于深港通下的港股通标的证券名单调整的公告》，本公司被调入沪港通与深港通下港股通标的名单，自2026年3月9日起正式生效。沪港通及深港通是香港与中国内地的资本市场投资者之间的股票交易与投资的渠道。董事会认为，本公司被调入沪港通与深港通下港股通标的名单，将有助于扩大本公司的股东群体并提升本公司股份的交易流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VT","BK4588","VXUS","BK1191","02575","BK4585"],"gpt_icon":0},{"id":"2617687075","title":"轩竹生物-B盘中异动 早盘快速跳水5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617687075","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617687075?lang=zh_cn&edition=full","pubTime":"2026-03-06 11:09","pubTimestamp":1772766558,"startTime":"0","endTime":"0","summary":"2026年03月06日早盘11时09分，轩竹生物-B股票出现波动，股价快速跳水5.27%。截至发稿，该股报50.300港元/股，成交量20.65万股，换手率0.13%，振幅6.21%。轩竹生物-B股票所在的生物技术行业中，整体涨幅为2.61%。其相关个股中，药捷安康-B、宜明昂科-B、百奥赛图-B涨幅较大，振幅较大的相关个股有药捷安康-B、百奥赛图-B、映恩生物-B，振幅分别为25.74%、12.13%、11.61%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030611091897a84bac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026030611091897a84bac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","BK1191"],"gpt_icon":0},{"id":"2616583635","title":"轩竹生物-B盘中异动 早盘大幅跳水5.08%报57.900港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616583635","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616583635?lang=zh_cn&edition=full","pubTime":"2026-03-04 09:40","pubTimestamp":1772588402,"startTime":"0","endTime":"0","summary":"2026年03月04日早盘09时40分，轩竹生物-B股票出现波动，股价急速跳水5.08%。截至发稿，该股报57.900港元/股，成交量2.7万股，换手率0.02%，振幅4.26%。轩竹生物-B股票所在的生物技术行业中，整体跌幅为0.75%。其相关个股中，和誉-B、晶泰控股、三叶草生物-B涨幅较大，振幅较大的相关个股有帝王国际投资、康诺亚-B、晶泰控股，振幅分别为10.09%、8.15%、6.39%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603040940029542df4b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202603040940029542df4b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2616317315","title":"轩竹生物-B(02575)：轩悦宁®第三个适应症上市申请获得NMPA批准，用于一线治疗HR+/HER2-晚期乳腺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2616317315","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616317315?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:41","pubTimestamp":1772527312,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，本公司自主研发的创新药吡洛西利片联合芳香化酶抑制剂一线治疗HR+/HER2-晚期乳腺癌的新适应症上市申请，已获得中国国家药品监督管理局批准上市。HR+/HER2-乳腺癌是中国最高发的亚型，占病例总数约75%，HR+/HER2 乳腺癌患者中约有30%被诊断为晚期乳腺癌。BRIGHT-3 研究是一项在中国58家中心开展的随机、双盲的III期临床试验，旨在评估吡洛西利联合来曲唑或阿那曲唑一线治疗HR+/HER2-晚期乳腺癌的有效性和安全性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1409452.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4203","HR","BK4225","BK1191","02575"],"gpt_icon":0},{"id":"1171371156","title":"轩竹生物-B：宣愈宁比瑞西利片补充新药申请获批新适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1171371156","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171371156?lang=zh_cn&edition=full","pubTime":"2026-03-03 16:40","pubTimestamp":1772527222,"startTime":"0","endTime":"0","summary":"轩竹生物-B（股票代码：02575）近日宣布，其核心产品宣愈宁比瑞西利片（Xuanyuening Bireociclib Tablets）的补充新药申请已获得监管机构批准，新增一项重要适应症。此次获批标志着该药物在临床应用范围的进一步拓展，有望为特定患者群体提供新的治疗选择。\n比瑞西利片作为轩竹生物研发的创新药物，此次新适应症的获批将强化其在相关治疗领域的市场竞争力。公司表示，将积极推进该药物的商业化进程，以满足未竟的临床需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2613227810","title":"四环医药(00460.HK)附属轩竹生物获纳入恒生综合指数成份股","url":"https://stock-news.laohu8.com/highlight/detail?id=2613227810","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613227810?lang=zh_cn&edition=full","pubTime":"2026-02-22 18:37","pubTimestamp":1771756621,"startTime":"0","endTime":"0","summary":"格隆汇2月22日丨四环医药公告，根据恒生指数有限公司于2026年2月13日公布的截至2025年12月31日止期间恒生指数系列季度检讨结果，集团旗下非全资附属公司轩竹生物科技股份有限公司被纳入恒生综合指数成分股，该调整将于2026年3月9日正式生效。 恒生综合指数作为港股综合性基准指标，全面覆盖在香港联交所主板上市、累计市值位列前95%的上市企业。获纳入恒生综合指数成分股，轩竹生物股份预计将符合沪港通及深港通交易的纳入标准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260222/32021373.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02575","BK1191","BK1600","BK1515","00460","BK1593","HSCI"],"gpt_icon":0},{"id":"2613221082","title":"轩竹生物-B(02575)获纳入恒生综合指数成分股","url":"https://stock-news.laohu8.com/highlight/detail?id=2613221082","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613221082?lang=zh_cn&edition=full","pubTime":"2026-02-22 18:07","pubTimestamp":1771754870,"startTime":"0","endTime":"0","summary":"智通财经APP讯，轩竹生物-B 发布公告，根据恒生指数有限公司于2026年2月13日公布的截至2025年12月31日止期间的恒生指数系列季度检讨结果，公司被纳入恒生综合指数的成分股，该调整将于2026年3月9日正式生效。获纳入恒生综合指数成分股，公司股份预计将符合沪港通及深港通交易的纳入标准。董事会认为，公司获纳入恒生综合指数成份股，反映投资者对公司价值与成长潜力的认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02575","BK1191","HSCI"],"gpt_icon":0},{"id":"2611425156","title":"轩竹生物-B(02575)获纳入恒生综合指数 有望成为港股通标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2611425156","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611425156?lang=zh_cn&edition=full","pubTime":"2026-02-13 19:26","pubTimestamp":1770982006,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2月13日，恒生指数公司宣布截至2025年12月31日之恒生指数系列季度检讨结果，其中轩竹生物-B(02575)获纳入恒生综合指数。变动将于2026年3月6日(星期五)收市后实施并于2026年3月9日(星期一)起生效，届时沪深交易所会相应调整港股通可投资标的范围。据中金研报，轩竹生物有可能被调入港股通，因其满足了包括市值、流动性和上市时间等在内的一系列标准。2025年12月7日，国家医疗保障局公布2025年国家医保药品目录调整结果，轩竹生物自主研发的1类创新药、CDK4/6抑制剂吡洛西利片成功纳入目录，为晚期乳腺癌患者带来医保报销新福利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1405337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4585","BK4588","VT","HSCI","02575","VXUS"],"gpt_icon":0},{"id":"2610891405","title":"轩竹生物-B盘中异动 下午盘股价大跌5.44%报64.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610891405","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610891405?lang=zh_cn&edition=full","pubTime":"2026-02-12 13:35","pubTimestamp":1770874512,"startTime":"0","endTime":"0","summary":"2026年02月12日下午盘13时35分，轩竹生物-B股票出现异动，股价大幅跳水5.44%。截至发稿，该股报64.300港元/股，成交量35.65万股，换手率0.22%，振幅6.18%。资金方面，该股资金流入1121.31万港元，流出1071.88万港元。轩竹生物-B股票所在的生物技术行业中，整体跌幅为0.21%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602121335129540d8e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602121335129540d8e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575","BK1191"],"gpt_icon":0},{"id":"2610681325","title":"轩竹生物-B盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610681325","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610681325?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:24","pubTimestamp":1770603859,"startTime":"0","endTime":"0","summary":"2026年02月09日早盘10时24分，轩竹生物-B股票出现波动，股价快速拉升5.05%。截至发稿，该股报72.800港元/股，成交量4.4万股，换手率0.03%，振幅5.48%。轩竹生物-B股票所在的生物技术行业中，整体涨幅为1.77%。其相关个股中，歌礼制药-B、北海康成-B、中国抗体-B涨幅较大，振幅较大的相关个股有北海康成-B、奥星生命科技、旺山旺水-B，振幅分别为10.03%、8.75%、8.34%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209102419a6e400de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260209102419a6e400de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2609510330","title":"轩竹生物-B盘中异动 股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609510330","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609510330?lang=zh_cn&edition=full","pubTime":"2026-02-06 14:07","pubTimestamp":1770358072,"startTime":"0","endTime":"0","summary":"2026年02月06日下午盘14时07分，轩竹生物-B股票出现波动，股价急速拉升5.19%。截至发稿，该股报69.950港元/股，成交量28.9605万股，换手率0.18%，振幅7.44%。轩竹生物-B股票所在的生物技术行业中，整体涨幅为0.70%。其相关个股中，歌礼制药-B、诺诚健华、亿腾嘉和涨幅较大，振幅较大的相关个股有歌礼制药-B、创胜集团-B、诺诚健华，振幅分别为17.31%、13.75%、13.51%。轩竹生物-B公司简介：轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206140752a6da37ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206140752a6da37ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2609514892","title":"四环医药仿制药触底中，轩竹生物成功分拆，创新药进入收获期，惠升生物布局糖尿病全管线也迎","url":"https://stock-news.laohu8.com/highlight/detail?id=2609514892","media":"第一上海","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609514892?lang=zh_cn&edition=full","pubTime":"2026-02-06 13:14","pubTimestamp":1770354864,"startTime":"0","endTime":"0","summary":"公司正处于从传统仿制药向“医美+创新药”双轮驱动的战略转型期。预计到2028年，医美板块收入将达到40亿元左右，复合增速超过50%。考虑到公司全面领先的医美管线布局及其未来的盈利能力，建议投资者重点关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206133039a4832565&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260206133039a4832565&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1515","BK1593","BK1191","BK1574","02575","06978","00460","BK1600"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xuanzhubio.com","stockEarnings":[{"period":"1week","weight":-0.0266},{"period":"1month","weight":-0.2194},{"period":"3month","weight":-0.3005},{"period":"6month","weight":3.2966},{"period":"ytd","weight":-0.293}],"compareEarnings":[{"period":"1week","weight":-0.0084},{"period":"1month","weight":-0.0451},{"period":"3month","weight":-0.0074},{"period":"6month","weight":-0.0393},{"period":"1year","weight":0.0294},{"period":"ytd","weight":-0.0051}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"轩竹生物科技股份有限公司是一家主要从事生物制药业务的中国公司。该公司主要从事研发、生产及商业化创新药的业务，专注于消化、肿瘤和非酒精性脂肪性肝炎（NASH）等多个治疗领域。该公司主要产品包括KBP-3571、XZP-3287及XZP-3621。该公司主要在中国国内开展业务。","exchange":"SEHK","name":"轩竹生物-B","nameEN":"XUANZHUBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"轩竹生物-B,02575,轩竹生物-B股票,轩竹生物-B股票老虎,轩竹生物-B股票老虎国际,轩竹生物-B行情,轩竹生物-B股票行情,轩竹生物-B股价,轩竹生物-B股市,轩竹生物-B股票价格,轩竹生物-B股票交易,轩竹生物-B股票购买,轩竹生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}